MedinCell receives 7,5 M€ from the European Bank of Investment (EIB)
07/23/2019
Latest news
Third long-acting injectable antipsychotic using MedinCell’s technology enters preclinical development
Fast expanding portfolio
Already 5 programs in Preclinical & Clinical
Our pipeline
LEAD FORMULATION RESEARCH
| mdc-WWM CONTRACEPTION PARTNER: GATES FOUNDATION | mdc-NVA PAIN |
| mdc-GRT ORGAN TRANSPLANT | mdc-DOM UROLOGY |
PRECLINICAL & CLINICAL DEVELOPMENT
IMPACT HEALTH
Business model
Building a global pharma leader through long-acting injectables working with NGOs, Private Sector, and Academics
Who we are
Who we are
Our strength is our people
MedinCell is operated by our talented employees who have come together from around the world to achieve our mission of Better Medicine for All.
Through purposeful innovation, we aim to improve the treatments available to patients. And we believe that everyone should have access to best-in-class medication, so we focus on making our products available regardless of local economic conditions. To ensure access, we work on both for-profit and non-profit projects, in collaboration with highly valued partners ranging from big pharmas to physicians, from biotech firms to academics and foundations. Most importantly, our partners share our values based on trust and transparency.
